Persons with chronic kidney disease (CKD), diabetes, or heart failure treated with renin-angiotensin-aldosterone system (RAAS)-blocking agents are at an increased risk for hyperkalemia.1-4 Although mild to moderate hyperkalemia (serum potassium, 5.0-6.0 mEq/L) is often asymptomatic, severe hyperkalemia (serum potassium > 6.0 mEq/L) can cause cardiac arrhythmias and death.1 Hyperkalemia also limits use of RAAS-blocking agents, which have heart- and kidney-protective effects. Treatment of hyperkalemia involves dietary potassium restriction, discontinuation of RAAS-blocking agents, and use of potassium-binding cation-exchange polymers to enhance gut elimination.